SCHEMBL22010261

SCHEMBL22010261

COC(=O)c1ccc(Br)cc1S(=N)(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.50
CA1 P00915 4/20 0.50
CA9 Q16790 4/20 0.50
CA5A P35218 1/20 0.50
CA12 O43570 3/20 0.46
CA7 P43166 2/20 0.46
CA14 Q9ULX7 2/20 0.46
PDK2 Q15119 1/20 0.46
PDK4 Q16654 1/20 0.46
NR4A2 P43354 1/20 0.44
GAA P10253 3/20 0.44
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 3/20 0.41
HSD17B10 Q99714 2/20 0.41
GLA P06280 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21962894 0.88 CA2 (0.61) CA2CA1CA9CA5ACA12
SCHEMBL1369472 0.83 NR4A2 (0.48) CA2CA1CA9CA5ACA12
SCHEMBL17078010 0.81 NR4A2 (0.47) CA2CA1CA9CA5ACA12
SCHEMBL17494875 0.80 SMN1; SMN2 (0.46) CA2CA1CA9CA5ACA12
SCHEMBL1368657 0.79 KDM4E (0.45) CA2CA1CA9CA5ACA12
SCHEMBL19202355 0.78 CA2 (0.61) CA2CA1CA9CA5ACA12
SCHEMBL29295507 0.78 NR4A2 (0.43) CA2CA1CA9CA5ACA12
SCHEMBL3839211 0.77 NR4A2 (0.54) CA2CA1CA9CA12CA7
SCHEMBL22010626 0.76 CA2 (0.44) CA2CA1CA9CA5ACA12
SCHEMBL21962927 0.76 CA1 (0.42) CA2CA1CA9CA5ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020102100-A9 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2022-01-06 WO disclosed
WO-2020102100-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed